*Middle East respiratory syndrome coronavirus* (MERS-CoV), a novel human virus that emerged in 2012, has caused significant respiratory disease and kindled fears of a SARS-like epidemic traversing the world ([@bb0020]). While lacking the rapid human-to-human spread seen with its SARS-CoV cousin, the outbreak of MERS-CoV has continued in the Middle East over the past three years and has lead to infection in 26 countries, \> 1500 cases, and \> 550 deaths ([@bb0045]). With periodic reintroduction from zoonotic sources and the possibility for further human adaptation, MERS-CoV remains a significant global public health threat and highlights the need for therapeutic countermeasures to limit infection and spread.

Despite several years of study, understanding of MERS-CoV infection has been limited by a variety of factors including difficulty accessing samples, limited autopsy data, and the lack of robust animal models of disease ([@bb0050]). However, a number of reports have provided both insights and tools for further study including extensive sequencing data, reverse genetic resources, and monoclonal antibodies for treatment of infection ([@bb0050]). In contrast, vaccine strategies have been limited due to the absence of robust animal models. Typically examined in mice, the presence of specific charge and glycosylation difference between human and rodent DPP4, the receptor for MERS-CoV, prevent infection ([@bb0030]). Therefore, the traditional approaches to study pathogenesis and vaccine efficacy have been stunted. The lack of a small animal model has shifted MERS-CoV research into larger *in vivo* models including non-human primates and ungulates ([@bb0010]). Koch\'s postulates were first achieved for MERS-CoV in rhesus macaques ([@bb0015]). Subsequently, other large animal models have been reported including marmosets, camels, rabbits, and alpacas and vary in their levels of MERS-CoV pathogenesis ([@bb0010]). While new small animal models have been described and continue to be developed, in the short term, non-human primates provide the best model for testing vaccines and therapeutics.

In these issues of *EBioMedicine*, Lan and colleagues describe vaccine studies in a non-human primate model of MERS-CoV infection ([@bb0025]). Building on previous studies in rhesus macaques with SARS-CoV ([@bb0040]), the report details the efficacy of a MERS vaccine based on a recombinant receptor binding domain (RBD) subunit. Their results indicate stimulation of both humoral and cellular immunity following vaccination and boost. Subsequent intra-tracheal challenge of vaccinated monkeys revealed partial protection from MERS-CoV induced pathogenesis including reduced pneumonia and viral titers. Having been tested for both SARS and MERS-CoV, the platform has potential as a rapid response vaccine approach for future emergent CoV outbreaks. Similarly, the platform could also be deployed in reservoir populations like camels that are thought to harbor the virus ([@bb0050]). However, this RBD-based vaccine failed to produce sterilizing immunity typically sought in the context of vaccination. Overall, the results demonstrate that in the rhesus macaque model, subunit vaccines that target the receptor-binding domain of MERS-CoV can offer some level of protection, but require further refinement to induce sterilizing immunity.

While the study shows promise for the receptor binding domain-based vaccine platforms, a number of other questions remain. The rhesus macaque model, which supports MERS-CoV replication, fails to recapitulate severe disease seen in humans. As such, the level of protection in these studies may underestimate the utility of the approach or, alternatively, provides only minor protection for human disease. Further study in more pathogenic models like the marmoset or with adapted viruses is required to decipher this question. Similarly, while the RBD-based platform drives protection, other aspects of vaccine efficacy cannot be tested in the macaque model. Previous work with a double inactivated SARS-CoV had shown efficacy in young mice ([@bb0035]); however, subsequent analysis in aged animals or with heterologous challenge revealed vaccine failure and significant immune pathology ([@bb0005]). While not tested in experimental systems, based on reported cases, age and immuno-compromised status appears to be co-morbidity factors for MERS-CoV infection and lethality ([@bb0020], [@bb0050]). Therefore, testing the efficacy of any vaccine in aged and immune compromised populations must be considered. In addition, the continued reintroduction of MERS-CoV from zoonotic sources increases the likelihood of exposure to heterologous virus. With the focus of this vaccine on the RBD of MERS, the possibility of vaccine-induced immune pathology is reduced; however, in vivo testing is required to confirm this result.

Overall, the report by Lan and colleagues details a promising MERS-RBD-based platform for vaccine development. The combination of strong neutralization and reduced pathogenesis in the rhesus macaques indicates that the approach is worth pursuing. However, additional studies are required in models that can capture pathogenesis seen in humans, efficacy in aged populations, and possibility of immune pathology due to heterologous challenge. Despite these caveats, the success of the RBD-based approach has important implications for both MERS treatment as well as for rapid vaccine development platforms for future emergent CoV outbreaks.
